Repligen Corp Appoints New CFO, Elects Directors

Ticker: RGEN · Form: 8-K · Filed: Jun 14, 2024 · CIK: 730272

Repligen Corp 8-K Filing Summary
FieldDetail
CompanyRepligen Corp (RGEN)
Form Type8-K
Filed DateJun 14, 2024
Risk Levelmedium
Pages5
Reading Time7 min
Key Dollar Amounts$0.01, $750,000, $5,000,000, $440,000
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-election, cfo-appointment

TL;DR

Repligen gets a new CFO and two new board members, effective mid-June.

AI Summary

Repligen Corporation announced on June 12, 2024, changes in its executive team. Effective June 12, 2024, Catherine M. Davis was appointed as the new Chief Financial Officer, succeeding Walter J. DeGrange, Jr. The company also announced the election of two new directors, Dr. Paul J. Hastings and Ms. Sarah E. Emrey, to its Board of Directors, effective June 10, 2024.

Why It Matters

This filing indicates significant leadership changes at Repligen, including a new CFO and board members, which could signal strategic shifts or a focus on financial oversight and governance.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and financial management.

Key Players & Entities

  • Repligen Corporation (company) — Registrant
  • Catherine M. Davis (person) — Appointed Chief Financial Officer
  • Walter J. DeGrange, Jr. (person) — Departing Chief Financial Officer
  • Dr. Paul J. Hastings (person) — Elected Director
  • Ms. Sarah E. Emrey (person) — Elected Director
  • June 12, 2024 (date) — Effective date for CFO appointment
  • June 10, 2024 (date) — Effective date for director election

FAQ

Who has been appointed as the new Chief Financial Officer of Repligen Corporation?

Catherine M. Davis has been appointed as the new Chief Financial Officer, effective June 12, 2024.

Who did Catherine M. Davis replace as CFO?

Catherine M. Davis replaced Walter J. DeGrange, Jr. as Chief Financial Officer.

When were the new directors elected to the Board?

Dr. Paul J. Hastings and Ms. Sarah E. Emrey were elected to the Board of Directors effective June 10, 2024.

What is Repligen Corporation's principal executive office address?

Repligen Corporation's principal executive offices are located at 41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is June 12, 2024.

Filing Stats: 1,646 words · 7 min read · ~5 pages · Grade level 11.4 · Accepted 2024-06-14 17:15:56

Key Financial Figures

  • $0.01 — ich registered Common Stock, par value $0.01 per share RGEN The Nasdaq Global Se
  • $750,000 — t will receive an annual base salary of $750,000 and will be eligible to receive an annu
  • $5,000,000 — h an aggregate grant date fair value of $5,000,000, 50% of which will be in the form of ti
  • $440,000 — eceive an initial annual base salary of $440,000 and will be eligible to receive an annu

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIGEN CORPORATION Dated: June 14, 2024 By: /s/ Tony J. Hunt Tony J. Hunt Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.